A single-center experience of treating PNH using complement inhibitors in Czechia

Jaroslav Čermák, MD, Institute of Hematology and Blood Transfusion (ÚHKT), Prague, Czechia, comments on the success of treating patients with paroxysmal nocturnal hemoglobinuria (PNH) using complement inhibitors at his center in Czechia. Prof. Čermák notes that the center has treated 21 patients with proximal or terminal complement inhibitors, achieving a total response rate of 84% and a 10-year survival rate of almost 100%. This is significantly higher than the survival rate of patients not on complement inhibitors. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Видео A single-center experience of treating PNH using complement inhibitors in Czechia канала VJHemOnc – Video Journal of Hematology & HemOnc